Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Pan Cancer T

Request full access

Pan Cancer T is a biotechnology company developing T cell receptor (TCR) T-cell therapy for solid tumors

Rotterdam, NetherlandsFounded 2020Biotech & Life Sciences

About Pan Cancer T

Pan Cancer T is a biotechnology company that originated from Erasmus MC, a prominent medical center. The company specializes in developing TCR T cell therapies, which are treatments that use a patient's own immune cells to target and destroy cancer cells. These therapies are designed to treat solid tumors, which are masses of tissue that can be cancerous.

Pan Cancer T focuses on creating therapies that target unique and proprietary intracellular markers. These markers are specific to cancer cells and are not found in healthy cells, which helps to minimize side effects and increase the effectiveness of the treatment. The company has identified 30 such targets, making their approach highly specialized and innovative.

The primary clients of Pan Cancer T are healthcare providers and institutions that treat cancer patients, particularly those with hard-to-treat solid tumors. The market it operates in is the oncology sector, which is the branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.

Pan Cancer T operates on a business model that involves research and development (R&D) of its therapies, followed by clinical trials to ensure safety and efficacy. Once these therapies are proven effective, they are commercialized and sold to healthcare providers. The company generates revenue through the sale of these therapies and potentially through partnerships and licensing agreements with larger pharmaceutical companies.

The company has received recognition for its innovative approach, including the Axon Innovation for Health Award in 2021. It has also secured additional funding from investors like Thuja Capital, which supports its ongoing research and development efforts.

In summary, Pan Cancer T is a cutting-edge biotechnology company focused on developing life-saving TCR T cell therapies for solid tumors, serving the oncology market, and generating revenue through the commercialization of its specialized treatments.

Source: Dealroom company data

Pan Cancer T in the Rotterdam ecosystem

Live from Dealroom

The Pan Cancer T office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed5 investors entered at this stage

  • Thuja Capital
  • Van Herk Investments
  • Swanbridge Capital
  • InnovationQuarter Capital
  • Erasmus University Medical Center

Series B and later1 investor entered at this stage

  • Government of the Netherlands
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇳🇱 Netherlands66.7%
🇬🇧 United Kingdom33.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Pan Cancer T on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Pan Cancer T on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.